Hemodynamic Effects of Brefanolol and Propranolol Assessed by Noninvasive Methods in Patients with Arterial Hypertension

@article{Halabi1990HemodynamicEO,
  title={Hemodynamic Effects of Brefanolol and Propranolol Assessed by Noninvasive Methods in Patients with Arterial Hypertension},
  author={Atef Halabi and W. Endell and Issam M. Halabi and Wilhelrn Kirch},
  journal={Journal of Cardiovascular Pharmacology},
  year={1990},
  volume={16},
  pages={81-86}
}
Summary: In a placebo-controlled, randomized, cross-over study, 16 patients (10 males, 6 females; 50.6 ± 10.4 years; body weight of 74.5 ± 8.9 kg; mean ±SD) with arterial hypertension (WHO stages I and II) were administered single oral doses of placebo, 80 mg of propranolol, as well as 50 and 100 mg of brefanolol (a β-adrenergic blocking agent with vasodilating properties) in order to determine the resulting hemodynamic effects. Blood pressure, heart rate, and various hemodynamic parameters… 
Antihypertensive Activity, Cardiac Performance and Pharmacokinetics of Bunazosin, a Novel α1-Adrenoceptor Antagonist, in Patients with Normal and Impaired Renal Function
TLDR
A close correlation between plasma concentrations and haemodynamic effects of bunazosin could be demonstrated and this novel α1-adrenoceptor antagonist was administered once daily for 2 weeks to 24 patients with hypertension.
Bunazosin in patients with impaired hepatic or renal function
TLDR
D dosage adjustment of the α1-receptor blocker in patients with impaired liver and kidney function appears to be mandatory, as there was a close correlation between plasma levels and antihypertensive activity of bunazosin in the present study.
Pharmacologic Therapy for Intermittent Claudication
TLDR
Treatment goals are aimed at decreasing cardiovascular risk, as well as improving quality of life, in patients with intermittent claudication, which is associated with cardiovascular risk and physical impairment.
Medical management of peripheral arterial disease
TLDR
This review focuses on the current available medical therapies for PAD, including risk‐factor modification and antiplatelet therapies, as well as strategies for symptomatic relief in both patients with intermittent claudication and patients with critical limb ischemia.
Naftidrofuryl for intermittent claudication.
TLDR
Oral naftidrofuryl has a statistically significant and clinically meaningful, although moderate, effect of improving walking distance in the six months after initiation of therapy for people with intermittent claudication.
Simultaneous Determination of (R)‐ and (S)‐Brefanolol in Human Plasma: High‐Performance Liquid Chromatographic Assay on a Chiral Stationary Phase
TLDR
A new method for the quantitative enantiospecific determination of rac‐brefanolol, a vasodilating β‐adrenoceptor blocking agent, in human plasma is described, and limits are 10 ng enantiomer per ml plasma to allow the performance of pharmacokinetic studies after the aimed therapeutic dosages.
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data
TLDR
Evidence is provided that naftidrofuryl has a clinically meaningful effect compared with placebo in improving walking distance in patients with intermittent claudication.
Hemodvnarnic effects famotidhe in patients
  • 2008
Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine
TLDR
The difference in the results for nizatidine and Famotidine can be explained by the longer half-life of famotidine, and vascular effects are assumed to be responsible for impairment of cardiac performance byfamotidine.
...
...